Dublin, Jan. 12, 2017 -- Research and Markets has announced the addition of the "Hospital Acquired Infections Forecast in 15 Major Markets 2017-2027" report to their offering.
Hospital acquired infections (HAI), or nosocomial infections - infections acquired by patients or staff during in-patient care (hospital admission). This is the point or annual prevalence of HAI (or HCAI), equivalent to a number of cases of an infection per year. HAI can be caused by any pathogen, including bacteria, viruses and fungi.
This report provides the current incident population for Hospital Acquired Infections across 15 Major Markets (USA, France, Germany, Italy, Spain, UK, Netherlands, Sweden, Norway, Denmark, Finland, Poland, Romania, Czech Republic and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Hospital Acquired Infections have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line Incidence for Hospital Acquired Infections
10. HAI by major site of infection
11. HAI by main pathogen
12. Treatment of HAIs
13. Abbreviations used in the report
14. Patient-Based Offering
15. Online Pricing Data and Platforms
16. References
17. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/5scl45/hospital_acquired
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs


Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 



